Serious infection across biologic-treated patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Annals of the Rheumatic Diseases

Volumn 77, Issue 6, 2018, Pages 905-910

  Rutherford, Andrew I ^a,b   Subesinghe, Sujith ^a   Hyrich, Kimme L ^c,d   Galloway, James B ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

dmards (biologic); epidemiology; infections; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BACTEREMIA; BONE INFECTION; DISEASE REGISTRY; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEPSIS; SKIN INFECTION; UNITED KINGDOM; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; AGED; CHEMICALLY INDUCED; FOLLOW UP; INCIDENCE; MIDDLE AGED; OPPORTUNISTIC INFECTION; REGISTER; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CERTOLIZUMAB PEGOL; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLIXIMAB; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REGISTRIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

EID: 85047238851     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-212825     Document Type: Article

References (19)

1. Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord 2016;17:322.
2. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
3. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011;13:R139.
4. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
5. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
6. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
7. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2:Cd008794.
8. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
9. Sakai R, Cho SK, Nanki T, et al. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 2015;17:74.
10. Watson K, Symmons D, Griffiths I, et al. The British Society for rheumatology biologics register. Ann Rheum Dis 2005;64:iv42-3.
11. Vallejo AA, Rutherford A, Filkova M, et al. SAT0099 Polypharmacy is associated with an increased risk of adverse outcomes in patients with rheumatoid arthritis. Annals of the rheumatic diseases 2017;76:806.
12. Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res 2014;66:990-7.
13. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk score for serious infections. Ann Rheum Dis 2014;73:1673-6.
14. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
15. Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74.
16. Richter A, Listing J, Schneider M, et al. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1667-73.
17. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41.
18. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351:929-33.
19. Qiu P, Cui X, Sun J, et al. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med 2013;41:2419-29.